BioSpace News Archive

Pharm Country

Lannett Launches Five New Products In Fiscal 2019 First Quarter

Lannett Company, Inc. today announced that it commenced marketing five new products in its recently completed fiscal 2019 first quarter, bringing to 12 the total number of products launched since January 1, 2018.

October 1, 2018
·
2 min read
Bio NC

TransEnterix Receives CE Mark Approval for Senhance Ultrasonic Instrument System

Receives CE Mark for Senhance™ Ultrasonic, Advanced Energy Capability Broadens the Potential Applicability of Senhance Surgery in CE Mark Countries

October 1, 2018
·
3 min read
Lone Star Bio

Stage Partners with the Breast Cancer Research Foundation to Raise Awareness and Funds

Guests are invited to participate in donations, dedications and deals

October 1, 2018
·
3 min read
Business

MD Anderson immunologist Jim Allison awarded Nobel Prize

T cell discoveries led to game-changing treatment revolutionizing cancer care

October 1, 2018
·
5 min read
Business

Bruker Announces Breakthrough Proteomics and Lipidomics Workflow Advances for the timsTOF™ Pro at HUPO 2018

First Large-Scale Use of Peptide CCS Values to Enhance Search Specificity

October 1, 2018
·
8 min read
Pharm Country

The Breast Cancer Research Foundation Marks 25 Years of Impact with Record-Breaking $63 Million Investment in Cancer Research Worldwide

BCRF announces priority research areas for 2018-2019

October 1, 2018
·
5 min read
Drug Development

CTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data Review

Trial to continue to full enrollment of all three treatment arms

October 1, 2018
·
6 min read
Drug Development

Viking Therapeutics Presents Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture in Plenary Oral Presentation at ASBMR 2018 Annual Meeting

Study Achieves Primary Endpoint, Demonstrating Statistically Significant, Dose-Dependent Increases in Lean Body Mass Ranging from 4.8% to 9.1% Following Treatment with VK5211

October 1, 2018
·
7 min read
Business

Hitachi Chemical Advanced Therapeutics Solutions Signs Three-Year Agreement with GSK to Provide Clinical Manufacturing for T Cell Therapy

HCATS will manufacture GSK’s SPEAR T-cell receptor therapy targeting NY-ESO-1 for the US, Canadian and European trials.

October 1, 2018
·
2 min read
BioMidwest

Data on Exicure’s TLR9 Agonist Spherical Nucleic Acid (SNA™) Construct Presented at the 4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

Exicure technology shows effective antitumor activity in mouse tumor models

October 1, 2018
·
3 min read